TScan Therapeutics: Potential Signs of a Stock Recovery
TScan Therapeutics, Inc. (TCRX) has experienced a notable decline recently, dropping 5.6% over the last month. However, the stock might be on the verge of a recovery. With its current status in the oversold category, analysts predict that the company could report better earnings than previously anticipated.
Understanding Oversold Stocks Using RSI
Relative Strength Index (RSI) is a popular tool for identifying oversold stocks. This technical indicator gauges the speed and change of price movements, helping investors assess market conditions.
The RSI ranges from zero to 100, with a common threshold for oversold conditions being an RSI reading below 30.
Every stock moves between being overbought and oversold, regardless of its underlying fundamentals. The RSI’s utility lies in its ability to highlight when a stock’s price is ripe for a reversal.
If a stock’s price falls significantly due to excessive selling, it may attract investors looking to benefit from a rebound. However, investors should note that RSI is only one piece of the puzzle and should be complemented with other analyses before making investment decisions.
What Could Drive TCRX’s Comeback?
TScan’s current RSI reading of 25.67 suggests that the recent heavy selling may be slowing down, indicating a possible bounce back toward a more balanced supply and demand.
Beyond technical readings, there are fundamental indicators supporting a potential recovery for TCRX. Analysts have recently revised their earnings estimates upward. In the past month, the consensus estimate for TCRX’s earnings per share (EPS) has risen by 0.9%. Generally, an increase in earnings revisions indicates a likelihood of stock price appreciation in the near future.
Additionally, TCRX holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 stocks based on earnings trends. This high ranking further reinforces expectations for a positive turnaround soon. For further insights, you can view the full list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>.
Access Zacks’ Insights for Just $1
This offer is genuine.
Years ago, we surprised our members by providing them 30-day access to all our selections for just $1, with no obligation to spend more.
Many have jumped at this opportunity, while others hesitated, thinking there might be a catch. The truth is, we simply want to introduce you to our services, such as Surprise Trader, Stocks Under $10, Technology Innovators, and others, which saw 228 positions closing with impressive double- and triple-digit gains in 2023 alone.
Download Zacks’ latest recommendations for free: 7 Best Stocks for the Next 30 Days.
TScan Therapeutics, Inc. (TCRX): Free Stock Analysis Report
Read the full article on Zacks.com here.
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
